Bell Rock Capital LLC Grows Stock Position in Johnson & Johnson (NYSE:JNJ)

Bell Rock Capital LLC boosted its position in Johnson & Johnson (NYSE:JNJGet Rating) by 469.7% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 8,346 shares of the company’s stock after buying an additional 6,881 shares during the period. Johnson & Johnson makes up approximately 1.7% of Bell Rock Capital LLC’s portfolio, making the stock its 15th largest holding. Bell Rock Capital LLC’s holdings in Johnson & Johnson were worth $1,363,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently bought and sold shares of JNJ. DORCHESTER WEALTH MANAGEMENT Co increased its holdings in shares of Johnson & Johnson by 8.6% in the 1st quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock valued at $14,975,000 after purchasing an additional 5,327 shares in the last quarter. Cantor Fitzgerald Investment Advisor L.P increased its holdings in Johnson & Johnson by 88.9% in the first quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock valued at $31,049,000 after buying an additional 82,429 shares in the last quarter. AMI Investment Management Inc. lifted its position in shares of Johnson & Johnson by 8.8% during the 1st quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock valued at $3,244,000 after acquiring an additional 1,475 shares during the period. Equitable Holdings Inc. boosted its stake in shares of Johnson & Johnson by 4.9% during the 1st quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock worth $8,095,000 after acquiring an additional 2,119 shares in the last quarter. Finally, USS Investment Management Ltd increased its stake in Johnson & Johnson by 2.4% in the 1st quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock valued at $152,488,000 after purchasing an additional 20,528 shares in the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.

Johnson & Johnson Stock Down 0.3 %

Shares of NYSE:JNJ opened at $173.43 on Tuesday. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69. The stock’s 50-day moving average price is $176.33 and its two-hundred day moving average price is $171.44. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37. The firm has a market cap of $453.43 billion, a price-to-earnings ratio of 24.15, a PEG ratio of 3.28 and a beta of 0.56.

Johnson & Johnson (NYSE:JNJGet Rating) last released its earnings results on Tuesday, October 18th. The company reported $2.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.49 by $0.06. The firm had revenue of $23.79 billion during the quarter, compared to the consensus estimate of $23.44 billion. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. Johnson & Johnson’s revenue was up 1.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.60 earnings per share. On average, research analysts forecast that Johnson & Johnson will post 10.04 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be issued a dividend of $1.13 per share. The ex-dividend date of this dividend is Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.61%. Johnson & Johnson’s payout ratio is 62.95%.

Insider Buying and Selling

In other Johnson & Johnson news, VP Peter Fasolo sold 22,864 shares of the company’s stock in a transaction dated Wednesday, October 19th. The stock was sold at an average price of $164.50, for a total transaction of $3,761,128.00. Following the completion of the sale, the vice president now directly owns 114,676 shares in the company, valued at $18,864,202. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, VP Peter Fasolo sold 22,864 shares of the business’s stock in a transaction dated Wednesday, October 19th. The stock was sold at an average price of $164.50, for a total transaction of $3,761,128.00. Following the completion of the sale, the vice president now owns 114,676 shares in the company, valued at approximately $18,864,202. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Joseph J. Wolk sold 14,781 shares of the firm’s stock in a transaction that occurred on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the completion of the transaction, the chief financial officer now owns 35,812 shares in the company, valued at approximately $6,431,835.20. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 300,750 shares of company stock valued at $52,311,677. 0.35% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Morgan Stanley reduced their price objective on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating for the company in a report on Tuesday, December 6th. StockNews.com began coverage on shares of Johnson & Johnson in a research note on Wednesday, October 12th. They issued a “strong-buy” rating on the stock. Atlantic Securities cut their target price on shares of Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a research report on Wednesday, October 19th. Citigroup raised their price objective on shares of Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a research note on Monday, December 12th. Finally, Bank of America lowered their target price on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a report on Friday, October 14th. Seven equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $182.42.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.